Literature DB >> 19086170

Reduced hepatic expression of adipose tissue triglyceride lipase and CGI-58 may contribute to the development of non-alcoholic fatty liver disease in patients with insulin resistance.

Masaki Kato, Nobito Higuchi, Munechika Enjoji.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19086170     DOI： 10.1080/00365520802008140

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN： 0036-5521            Impact factor:   2.423


× No keyword cloud information.
  15 in total

Review 1.  CGI-58: Versatile Regulator of Intracellular Lipid Droplet Homeostasis.

Authors:  Liqing Yu; Yi Li; Alison Grisé; Huan Wang
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

2.  Effects of insulin resistance and hepatic lipid accumulation on hepatic mRNA expression levels of apoB, MTP and L-FABP in non-alcoholic fatty liver disease.

Authors:  Nobito Higuchi; Masaki Kato; Masatake Tanaka; Masayuki Miyazaki; Shinichiro Takao; Motoyuki Kohjima; Kazuhiro Kotoh; Munechika Enjoji; Makoto Nakamuta; Ryoichi Takayanagi
Journal:  Exp Ther Med       Date:  2011-08-09       Impact factor: 2.447

3.  The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression.

Authors:  Munechika Enjoji; Ryoko Yada; Tatsuya Fujino; Tsuyoshi Yoshimoto; Masayoshi Yada; Naohiko Harada; Nobito Higuchi; Masaki Kato; Motoyuki Kohjima; Akinobu Taketomi; Yoshihiko Maehara; Manabu Nakashima; Kazuhiro Kotoh; Makoto Nakamuta
Journal:  Hepatol Int       Date:  2009-06-16       Impact factor: 6.047

4.  Adipose triacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice.

Authors:  S M Turpin; A J Hoy; R D Brown; C Garcia Rudaz; J Honeyman; M Matzaris; M J Watt
Journal:  Diabetologia       Date:  2010-09-15       Impact factor: 10.122

5.  NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.

Authors:  Munechika Enjoji; Kazuyuki Machida; Motoyuki Kohjima; Masaki Kato; Kazuhiro Kotoh; Kazuhisa Matsunaga; Manabu Nakashima; Makoto Nakamuta
Journal:  Lipids Health Dis       Date:  2010-03-12       Impact factor: 3.876

6.  Carboxylesterase 2 prevents liver steatosis by modulating lipolysis, endoplasmic reticulum stress, and lipogenesis and is regulated by hepatocyte nuclear factor 4 alpha in mice.

Authors:  Yuanyuan Li; Munaf Zalzala; Kavita Jadhav; Yang Xu; Takhar Kasumov; Liya Yin; Yanqiao Zhang
Journal:  Hepatology       Date:  2016-03-15       Impact factor: 17.425

7.  Protein kinase STK25 controls lipid partitioning in hepatocytes and correlates with liver fat content in humans.

Authors:  Manoj Amrutkar; Matthias Kern; Esther Nuñez-Durán; Marcus Ståhlman; Emmelie Cansby; Urszula Chursa; Elin Stenfeldt; Jan Borén; Matthias Blüher; Margit Mahlapuu
Journal:  Diabetologia       Date:  2015-11-09       Impact factor: 10.122

8.  Validation of the Antidiabetic and Hypolipidemic Effects of Clitocybe nuda by Assessment of Glucose Transporter 4 and Gluconeogenesis and AMPK Phosphorylation in Streptozotocin-Induced Mice.

Authors:  Chun-Ching Shih; Mei-Hsing Chen; Cheng-Hsiu Lin
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-03       Impact factor: 2.629

9.  Identification of an intrinsic lysophosphatidic acid acyltransferase activity in the lipolytic inhibitor G0/G1 switch gene 2 (G0S2).

Authors:  Xiaodong Zhang; Xitao Xie; Bradlee L Heckmann; Alicia M Saarinen; Haiwei Gu; Rudolf Zechner; Jun Liu
Journal:  FASEB J       Date:  2019-02-25       Impact factor: 5.834

10.  Antidiabetic and Antihyperlipidemic Effects of Clitocybe nuda on Glucose Transporter 4 and AMP-Activated Protein Kinase Phosphorylation in High-Fat-Fed Mice.

Authors:  Mei-Hsing Chen; Cheng-Hsiu Lin; Chun-Ching Shih
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-16       Impact factor: 2.629
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.